Investment analysts at StockNews.com started coverage on shares of NeuroMetrix (NASDAQ:NURO – Get Free Report) in a research report issued on Thursday. The brokerage set a “sell” rating on the medical device company’s stock.
NeuroMetrix Price Performance
NASDAQ NURO opened at $3.57 on Thursday. The firm has a market cap of $7.10 million, a P/E ratio of -0.57 and a beta of 2.26. The stock’s 50-day moving average is $3.74 and its 200-day moving average is $3.82. NeuroMetrix has a one year low of $2.70 and a one year high of $11.82.
NeuroMetrix (NASDAQ:NURO – Get Free Report) last released its quarterly earnings results on Thursday, February 22nd. The medical device company reported ($1.43) EPS for the quarter. The business had revenue of $1.32 million for the quarter. NeuroMetrix had a negative return on equity of 31.31% and a negative net margin of 110.64%.
Institutional Investors Weigh In On NeuroMetrix
About NeuroMetrix
NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies.
Further Reading
- Five stocks we like better than NeuroMetrix
- Comparing and Trading High PE Ratio Stocks
- United Airlines Soars on Earnings Beat
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- J.B. Hunt Hits the Skids: Lower Prices to Come
- CD Calculator: Certificate of Deposit Calculator
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for NeuroMetrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroMetrix and related companies with MarketBeat.com's FREE daily email newsletter.